miRNA World, Boston, MA 28-30 October 2014
Upcoming SlideShare
Loading in...5
×
 

miRNA World, Boston, MA 28-30 October 2014

on

  • 689 views

miRNA World 2014 has been designed to take advantage of the explosion in miRNA research to harness the potential of these non-coding RNA’s. ...

miRNA World 2014 has been designed to take advantage of the explosion in miRNA research to harness the potential of these non-coding RNA’s.

With developments and advancements occurring all the time, miRNA World 2014 finds itself at the forefront of miRNA research and development.

Designed and constructed to harness the potential of miRNAs in a variety of research arenas, miRNA World 2014 will help maximize the therapeutic potential locked in these unique non-coding regions of the genome.

A meeting dedicated to engagement, collaboration and networking, miRNA World 2014 will address and discuss critical topics in the sector, including, miRNA biomarkers inside and outside of cancer, miRNA’s as diagnostics with particular focus on exosomal markers, the delivery, and pharmacological and efficacy challenges associated with both miRNA Mimics and Anti-miR’s.

Statistics

Views

Total Views
689
Views on SlideShare
505
Embed Views
184

Actions

Likes
0
Downloads
3
Comments
0

1 Embed 184

https://twitter.com 184

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

miRNA World, Boston, MA 28-30 October 2014 miRNA World, Boston, MA 28-30 October 2014 Document Transcript

  • Sponsors: RESEARCHED & DEVELOPED BY: Discover the Pre-clinical, Diagnostic & Therapeutic Application of miRNAs EXPERT SPEAKERS INCLUDE: Frank Slack Professor, Molecular, Cellular & Developmental Biology Yale School of Medicine Carl Novina Associate Professor, Microbiology & Immunology Dana-Farber Cancer Institute David Rodman Executive Vice President, Research & Development miRagen Therapeutics Sinil Kim Chief Medical Officer, Vice President, Oncology miRNA Therapeutics Roel Schaapveld Chief Executive Officer InteRNA Technologies Pavan Kumar Senior Scientist Eisai George Calin Professor, Department of Experimental Therapeutics MD Anderson Cancer Center Hungyun Lin Principal Scientist Pfizer Anders Näär Professor, Cell Biology Harvard Medical School Tel: +1 212 537 5898 | Email: info@hansonwade.com www.micro-rna-world.com October 28th-30th 2014 BOSTON, MA
  • miRNA World 2014 Boston | October 28th-30th Tel: +1 212 537 5898 | Email: info@hansonwade.com www.micro-rna-world.com WELCOME TO miRNA World 2014: Crucial Topics – The topics addressed and discussed at miRNA World are generated by and for the miRNA community to reflect the most pressing challenges and opportunities in this dynamic space. Tackling these topics in- depth will allow you to maximize the potential of your miRNA research. Expert Individuals – miRNA World 2014 brings together the key opinion leaders across academia, pharma and biotech who are revolutionizing the field of miRNA research. Learn from and network with these individuals and discover what make this field tick. Interactive Formats – Utilizing an array of dynamic interactive formats, miRNA World cultivates in-depth discussions which will yield tangible results. Take advantage as we break down the boundaries between institutions and debate best practice in the key topics areas which are yet to settle on definitive answers. WHAT MAKES miRNA WORLD 2014 SPECIAL? CONTENTS Speakers:  3 Conference Day One:  4-5 Conference Day Two:  6-7 Review the Workshop:  8 Sponsors:  8 The Venue & Pricing Options:  9 Harness the Clinical Potential of miRNAs miRNA World 2014 will enable you to take advantage of the burgeoning potential and applications of miRNAs by showcasing the leading advancements in the field. Research and development of the non-coding genome is rapidly maturing and miRNAs are the leading light in this dynamic field. miRNA World 2014 will bring you together with the experts who are shaping this landscape and driving us into this new realm of discovery. Unearth the therapeutic potential of miRNA Mimics and Anti-miR’s by gaining first hand knowledge from those who are conducting the leading pre-clinical and clinical trials with these compounds. Realize the biomarker and diagnostic applications of miRNAs across a spectrum of disease areas and witness how these are providing precise tools in order to deliver more personalized patient care. Replicate success from the leaders in the field as we: 1. Overcome the key therapeutic delivery challenges by blueprinting your success from those who are breaking the delivery bottleneck 2. Accelerate your development of miRNA diagnostic tests and assays through the application of exosomal and cellular miRNAs 3. Develop a comprehensive pharmacology strategy for miRNA therapeutics through optimizing drug efficacy and safety 4. Construct a complete toolkit to maximize your research in the burgeoning field of miRNA biomarkers 5. Bridge the knowledge gap between miRNA biogenesis and its effect on clinical research and drug discovery Leave miRNA World 2014 brimming with new ideas, tools and connections to maximize the potential of your miRNA research.
  • SPEAKER FACULTY It exceeded my expectations. The talks were high quality and the interaction among participants was excellent. Genentech miRNA World 2014 Boston | October 28th-30th Tel: +1 212 537 5898 | Email: info@hansonwade.com www.micro-rna-world.com SEARCH GROUPS FOR: miRNA World 2014 to join the online community. David Rodman Executive Vice President, Research & Development Pavan Kumar Senior Scientist Usha Singh Senior Scientist & Scientific Lead George Calin Professor, Department of Experimental Therapeutics Hungyun Lin Principal Scientist Lorenzo Sempere Assistant Professor, Center for Translational Medicine Quan Lu Associate Professor, Environmental Genetics & Pathophysiology Anders Näär Professor, Cell Biology Gyongyi Szabo Professor & Vice Chair for Research Andrei Thomas-Tikhonenko Professor & Division Chief Mark Feinberg Associate Professor, Medicine Carl Novina Associate Professor, Microbiology and Immunology Frank Slack Professor, Molecular, Cellular & Developmental Biology Sinil Kim Chief Medical Officer, Vice President, Oncology Andrea Kasinski Assistant Professor, Biological Sciences Robert Lee Professor, Pharmaceutics Elisa Romeo Senior Director, Research & Development Roel Schaapveld Chief Executive Officer
  • CONFERENCE DAY ONE 8.00 Registration and Breakfast 9.00 Chair’s Opening Remarks Andrea Kasinski, Assistant Professor, Biological Sciences, PurdueUniversity 9.10 Conversations that Matter Close your laptops, put down your cell phones and eavesdrop on exclusive one-on- one interviews played out on stage with key opinion leaders in the field of miRNA research. Through interactive dialogue, this will be your ONLY opportunity be part of an exclusive conversation between those revolutionizing the miRNA field as they discuss: • What are the opportunities with miRNA’s as biomarkers? • Where are we heading with miRNA’s as diagnostics? • miRNA Anti-miR’s: What promise do these therapeutics hold? • miRNA Mimics: What promise do these therapeutics hold? • How much fundamental biology is left to uncover? • What does the future of miRNA research look like? 10.00 Panel Discussion and Open Q&A: What is the clinical potential of mirna’s in research and development and what hurdles must be overcome to maximize this potential? Frank Slack, Professor, Molecular, Cellular & Developmental Biology, Yale School of Medicine George Calin, Professor, Department of Experimental Therapeutics, MD Anderson Cancer Center David Rodman, Executive Vice President, Research & Development, miRagen Therapeutics 10.20 Enhanced miRNA Activity is a Novel Oncogenic Function of eIF4F • eIF4E, a component of eIF4F, is thought to be  increased in cancers to sustain increased growth. • We show that increased eIF4E has oncogenic functions through enforcement of microRNA activity. Carl Novina, Associate Professor, Microbiology & Immunology, Dana-Farber Cancer Institute 10.50 Speed Networking & Morning Refreshments miRNA Target Validation & Clinical Biomarkers 11.50 miRNAs in Airway Smooth Muscle Proliferation and Asthma • Expression profiling of microRNAs in human airway smooth muscle (ASM). • miR-10a controls ASM proliferation via targeting of PI3 kinase pathway. • miR-10a as a therapeutic target to reduce ASM proliferation in asthma. Quan Lu, Associate Professor, Environmental Genetics & Pathophysiology, Harvard School of Public Health 12.20 Circulating miRNAs as Potential Non-Invasive Biomarkers in Patients of T Helper-Mediated Diseases • Implications for the utilization of circulating miRNA profiles as clinical biomarkers for T-helper associated associated disease detection and patient stratification. • Considerations of miRNA profiling platform selections, sample preparation in clinical specimens, and computational support of data analysis. Hungyun Lin, Principal Scientist, Pfizer miRNA World 2014 Boston | October 28th-30th Tel: +1 212 537 5898 | Email: info@hansonwade.com www.micro-rna-world.com 29th OCTOBER 2014 Keynote Session Interactive Session Networking Session
  • 12.50 Detection and Applications of miRNAs in Drug Development • Describe optimal conditions and automated detection method for the detection of miRNAs in tissues. • Advantages and limitations of implementing miRNAs as a biomarker in drug development. Usha Singh, Senior Scientist, Scientific Lead, Merck 1.20 Poster Session & Networking Lunch miRNA-Based Diagnostics 2.20 Regulation of IGF1R Expression and Signaling by Polymorphisms in 3’UTR in Neuroblastoma: Implications for Therapy • IGF1R expression levels correlate with 3’UTR SNPs, which map to putative miRNA binding sites. • Certain 3’UTR haplotypes correlate with more robust PI3K signaling in the face of therapy, potentially leading to chemoresistance. Andrei Thomas-Tikhonenko, Professor & Division Chief, Children’s Hospital of Philadelphia 2.50 miRNAs: Biomarkers, Diagnostics and Beyond • Discovery and clinical validation of miRNAs as biomarkers in the blood. • Clinical laboratory product development and analytical validation. Elisa Romeo, Senior Director, Research & Development, Gensignia 3.05 Circulating miRNAs for Alzheimer’s Disease: This Promise and the Challenges • Discovery and validation of circulating 7-miRNA signature for AD. • Protocol optimization and longitudinal effect on signature miRNAs. Pavan Kumar, Senior Scientist, Eisai 3.35 miRNA Tissue-Based Diagnostics: Where are we Heading? • in situ co-detection of microRNAs and proteins for high-content marker analysis at single cell resolution. • Implementation of fully automated pipeline from tissue slide to image analysis in translational and clinical settings. • Prognostic application of miR-21 expression in tumor stroma in triple negative breast cancer and miR-34 expression in tumor epithelial in bladder cancer. Lorenzo Sempere, Assistant Professor, Center for Translational Medicine, Van Andel Institute 4.05 Afternoon Refreshments micro-Discussions 4.35 The miRNA World speaker faculty is second to none but there is just as much knowledge in the audience as there is onstage. Discover multiple perspectives on the key issues during roundtable discussions, specifically to facilitate peer-to-peer learning. • miRNA Normalization Goals & Approaches – What approaches are out there and what is generating the most success? • Polymorphism of 3’UTR – What clinical potential does this region hold? • Fundamental Understanding of miRNA Biology – Where are the gaps in our understanding and what does this mean from a therapeutic stand-point? • Exosomal miRNAs as Biomarkers - How important are these non-invasive biomarkers and what are their clinical applications. Moderators Andrei Thomas-Tikhonenko, Professor & Division Chief, Children’s Hospital of Philadelphia Pavan Kumar, Senior Scientist, Eisai 5.35 Close of Day 1 miRNA World 2014 Boston | October 28th-30th Tel: +1 212 537 5898 | Email: info@hansonwade.com www.micro-rna-world.com
  • CONFERENCE DAY Two 9.00 Chair’s Opening Remarks Andrea Kasinski, Assistant Professor, Biological Sciences, PurdueUniversity miRNA Therapeutic Delivery Methods 9.10 Development of the First microRNA Mimic in Clinic, MRX34 • Screening and selection of miRNA-mimic delivery systems. • Preclinical studies leading to first-in-human phase I study. • Design of phase I study and the interim results of phase I study. Sinil Kim, Chief Medical Officer, Vice President, Oncology, MiRNA Therapeutics 9.40 Delivery of a miRNA Mimic for Acute and Chronic Inflammatory Disease • Understand emerging miRNA mimic delivery strategies for targeting tissues and cell types relevant in acute and chronic inflammatory disease states. • Gain mechanistic insights into how systemic miRNA mimic delivery can alter disease targets in a cell-specific manner. Mark Feinberg, Associate Professor, Medicine, Brigham and Women’s Hospital 10.10 Interactive Solution Finding: Your Chance to Discuss How to Master miRNA Mimic Delivery Use this interactive session to make your voice heard on the challenges and opportunities engulfing miRNA replacement delivery and crowd-source solutions to the problems you are facing. • How are we going to master the Mimic specific delivery challenges? • How much is the delivery bottleneck holding back miRNA mimics and what advantages do certain delivery methods have over others? Sinil Kim, Chief Medical Officer, Vice President, Oncology, MiRNA Therapeutics Mark Feinberg, Associate Professor, Medicine, Brigham and Women’s Hospital 10.40 Morning Refreshments 11.10 Targets and Approaches for miRNA-Based Therapies in Liver Diseases • The microRNA signature of liver damage and inflammation is different depending on the type of liver disease. • Kupffer cell activation, a central component of steatoheptitis, is regulated by miRN-155 which is a feasible target for therapeutic approaches. Gyongyi Szabo, Professor & Vice Chair for Research, University of Massachusetts Medical School 11.40 A Functional Screening Approach to Identify miRNA Drug Candidates • Lentiviral-based miRNA expression library for high-throughput screening in cell- based assays. • Platform for identification miRNA biology. • Chemical modification and systemic delivery of miRNA mimics. Roel Schaapveld, Chief Executive Officer, InteRNA Technologies miRNA World 2014 Boston | October 28th-30th Tel: +1 212 537 5898 | Email: info@hansonwade.com www.micro-rna-world.com 30th OCTOBER 2014 Keynote Session Interactive Session Networking Session
  • 12.10 Interactive Solution Finding: Your Opportunity to Shape How the Field is Going to Master miRNA Anti-miR Delivery This session will provide the platform for the field to break the Anti-miR delivery bottleneck. Make your voice heard as we discuss with the experts: • How are we going to master the miRNA-Anti-miR specific delivery challenges? • What advantage do certain delivery methods hold over others? • How much is this delivery bottleneck holding back the therapeutic potential of Anti-miR’s? • What does the future look like for viral vectors? Gyongyi Szabo, Professor and Vice Chair for Research, University of Massachusetts Medical School Roel Schaapveld, Chief Executive Officer, InteRNA Technologies 12.40 Networking Lunch Developing miRNA Therapeutics: Efficacy and Safety 1.40 MicroRNAs as Therapeutic Targets in Cardiometabolic Diseases • Identification and characterization of microRNAs contributing to cholesterol/lipid- related diseases. • Evaluation of efficacy and safety of microRNA-targeting LNA antisense therapeutics in mice and non-human primates. Anders Näär, Professor, Cell Biology, Harvard Medical School 2.10 Interactive Solution Finding: Your Chance to Debate Whether There is an Optimal miRNA Therapeutic Pharmacology Strategy This interactive segment will debate what a desired pharmacological strategy for miRNA therapeutics looks like and what progress is being made on this front. Cultivate new ideas and innovative thoughts as to how your strategy can be optimized to deliver effective miRNA therapeutics. • Different chemistry platforms: Is this a one size fits all approach? • How much are off-target effects affecting the clinical utility of miRNA therapeutics? • How can we maximize efficacy in a cost-effective manner? Anders Näär, Professor, Cell Biology, Harvard Medical School 2.40 Afternoon Refreshments & Networking Delivering on the Promise of miRNA Therapeutics 3.10 micro-Discussion Intelligence and Open Q&A Missed a roundtable you wished you were at? Couldn’t write down all the high level discussion and opinion sharing? Fear not as roundtable moderators present the industry intelligence around the most pressing issues in the miRNA therapeutics. • What are the next moves with miRNA Therapeutics? • What needs to be done next on the maximize the potential of this field? • How can we implement key solutions to therapeutic challenges and what are the key outcomes to take forward? • What do we want to be talking about at miRNA World 2015? Andrea Kasinski, Assistant Professor, Biological Sciences, PurdueUniversity Andrei Thomas-Tikhonenko, Professor & Division Chief, Children’s Hospital of Philadelphia Pavan Kumar, Senior Scientist, Eisai 4.10 Close of Congress miRNA World 2014 Boston | October 28th-30th Tel: +1 212 537 5898 | Email: info@hansonwade.com www.micro-rna-world.com
  • CONFERENCE WORKSHOP SPONSORS miRNA World 2014 is proud to partner with: Gensignia Gensignia Life Sciences, Inc. is the US subsidiary of Gensignia Ltd, a privately held microRNA company specializing in microRNA signatures as diagnostic tools with offices in London, operations in San Diego, and research in Milan. Gensignia is developing proprietary molecular diagnostics designed to provide more accurate detection of cancer. In 2015, Gensignia intends to introduce a lung cancer diagnostic test in the US through its clinical laboratory (CLIA). www.gensignia.com miRNA World 2014 Boston | October 28th-30th Tel: +1 212 537 5898 | Email: info@hansonwade.com www.micro-rna-world.com Currently, one of the biggest challenge facing miRNA therapeutics is delivery. With a variety of delivery methods under development, the industry is still trying to adapt to what is on offer and keep up with the latest advancements in this space. Both anti-miRs and miRNA mimics possess their own set of challenges, but the delivery vesicles are applicable to both. Just another reason why there is so much invested interest in this field. This workshop will provide extensive levels of knowledge and detail on the current methods available for miRNA therapeutic delivery. Using first-hand case studies, you will learn what approaches work best for certain scenarios, what has already been learnt from pre-clinical and clinical studies and what approaches are going to lead the field over the next few years. Leave this workshop with: • A comprehensive understanding of the delivery methods that are showing success in pre-clinical and clinical studies • Extensive knowledge of how best to incorporate delivery methods into research strategies • The scientific and strategic foundations when considering what delivery vehicles to apply in your research Robert J. Lee, Ph.D., Professor of Pharmaceutics, is a member of the OSU Comprehensive Cancer Center, the OSU Nanotechnology Center NSF-NSEC and a faculty at OSU College of Pharmacy since 1997 (tenured since 2002). He is an expert on targeted nanoparticle and liposomal drug delivery systems. He obtained his Ph.D. in Biochemistry at Purdue University, worked as a Senior Scientist at GeneMedicine Inc. in 1995-1996 and then served as Vice President of R&D at Endocyte, Inc., where he was involved in the successful effort in taking 111In-DTPA-folate into a Phase I/II clinical trial. Workshop leader Robert Lee Professor of Pharmaceutics Ohio State University Mastering miRNA Therapeutic Delivery Date: 28th October 2014 | Time: 2.00pm – 5.00pm
  • Code:4528 * All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation. Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time. Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU Hanson Wade Limited. Registered in England & Wales. Company No: 6752216 TERMS & CONDITIONS VENUE AND ACCOMMODATION: REGISTER EVENT PRICES PRICING & VENUE Package Register & Pay before Friday June 13th* Register & Pay before Friday July 18th* Register & Pay before Friday August 22nd* Register & Pay before Friday September 26th * Standard Price* GOLD PACKAGE: Conference + 1 workshop $2698 (save $500) $2798 (save $400) $2898 (save $300) $2998 (save $200) $3098 (save $100) SILVER PACKAGE: Conference Only $2099 (save $400) $2199 (save $300) $2299 (save $200) $2399 (save $100) $2499 BRONZE PACKAGE: Workshop Only $699 ACADEMIC AND NOT-FOR-PROFIT Package Register & Pay before Friday June 13th* Register & Pay before Friday July 18th* Register & Pay before Friday August 22nd* Register & Pay before Friday September 26th * Standard Price* GOLD PACKAGE: Conference + 1 workshop $1498 (save $500) $1598 (save $400) $1698 (save $300) $1798 (save $200) $1898 (save $100) SILVER PACKAGE: Conference Only $1099 (save $400) $1199 (save $300) $1299 (save $200) $1399 (save $100) $1499 BRONZE PACKAGE: Workshop Only $499 miRNA World 2014 Boston | October 28th-30th Tel: +1 212 537 5898 | Email: info@hansonwade.com www.micro-rna-world.com Venue: The Westin Boston Waterfront Hotel is a AAA Four Diamond award-winner and is less than three miles from Logan International Airport, as well as a short cab, bus, water taxi, or T train ride away from Back Bay, the Financial District, and plenty of things to do in Boston. The Westin Boston Waterfront 425 Summer St, Boston, MA 02210, United States Accommodation: Overnight accommodation is not included in the registration fee, however accommodation options will be sent out with your confirmation email upon registering. www.micro-rna-world.com Tel: +1 212 357 5898 Email: register@hansonwade.com Mail: Hanson Wade 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU • 10% discount – 3 delegates • 15% discount – 4 delegates • 20% discount – 5 or more delegates Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. TEAM DISCOUNTS*